China Traditional Chinese Medicine stock, pharmaceuticals

China Traditional Chinese Medicine stock falls 11.11 percent

Published on 09/24/2026 at 03:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

China Traditional Chinese Medicine stock stood at HKD 1.12 on September 24, 2026, versus a 52-week high of HKD 2.68. First-half revenue fell 27.1 percent.

China Traditional Chinese Medicine stock, pharmaceuticals, first-half results, FTSE All-World Index, HKEX, Illustration mit AI erstellt.

China Traditional Chinese Medicine stock (ISIN HK0000056256) fell 11.11 percent to HKD 1.12 in Hong Kong trading on September 24, 2026, at 9:17 a.m. HKT. The price was 58.21 percent below its 52-week high of HKD 2.68, while the company reported a sharp deterioration in first-half results.

First-half revenue falls 27.1 percent

For the six months ended June 30, 2026, revenue fell 27.1 percent year over year to RMB 5.438 billion, according to Futunn. Gross profit declined 29.0 percent to RMB 2.581 billion, leaving the gross margin at 47.5 percent, down 1.2 percentage points from the prior-year period.

The earnings pressure was concentrated in the core formula-granules business. Revenue from that segment fell 35.4 percent to RMB 1.933 billion, while proprietary Chinese medicines declined 28.0 percent to RMB 1.663 billion in the first half.

Loss widens to RMB 776 million

Attributable loss reached RMB 776 million for the first half, widening 619.3 percent from the prior-year period, while basic loss per share widened 620.6 percent to RMB 0.1542, according to Futunn. A RMB 645 million goodwill impairment added to the pressure during the reporting period.

The figures give the stock decline a concrete operating backdrop: revenue contracted across the largest reported segments, while the loss grew much faster than sales fell. Formula granules represented 35.5 percent of first-half revenue, making that segment a key measure of any recovery in demand.

Index removal adds market pressure

Marketscreener reported on September 21, 2026, that China Traditional Chinese Medicine was dropped from the FTSE All-World Index, adding an identifiable market-structure change to the operating deterioration. The combination of a 27.1 percent revenue decline and a 619.3 percent wider loss leaves the first-half report as the central reference point for the shares.

Stock trades near yearly low

China Traditional Chinese Medicine stock was trading at HKD 1.12 on HKEX on September 24, 2026, down HKD 0.14 from the previous close of HKD 1.26. The market capitalization was HKD 5.640 billion on the same date, and the 52-week range was HKD 1.12 to HKD 2.68.